Efficacy and safety of transcutaneous tibial nerve stimulation combined with Mirabegron in the treatment of drug-refractory overactive bladder
10.3969/j.issn.1009-8291.2025.12.008
- VernacularTitle:经皮胫神经电刺激联合米拉贝隆治疗药物难治性膀胱过度活动症的有效性及安全性
- Author:
Jingde WU
1
;
Jianlin XIE
1
;
Qingwei ZHANG
1
;
Wengang YANG
2
;
Xiande HUANG
2
Author Information
1. The First Clinical Medical College of Gansu University of Chinese Medicine, Lanzhou 730000
2. Department of Urology, Gansu Provincial Hospital, Lanzhou 730000, China
- Publication Type:Journal Article
- Keywords:
overactive bladder;
drug-refractory overactive bladder;
transcutaneous tibial nerve stimulation;
Mirabegron
- From:
Journal of Modern Urology
2025;30(12):1064-1068
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of Mirabegron combined with transcutaneous tibial nerve stimulation (TTNS) in the treatment of drug-refractory overactive bladder (OAB), so as to alleviate patients'symptoms, improve their quality of life with optimized treatment plan, and provide reference for clinical practice. Methods A retrospective analysis was conducted on 56 patients with drug-refractory OAB treated at the Department of Urology of Gansu Provincial Hospital during Jan.2023 and Dec.2024. Based on the treatment methods, the patients were divided into two groups:the TTNS group and the combined treatment group, with 28 patients in either group. The daytime urination frequency, nocturia frequency, urgency episodes, urinary incontinence, functional bladder capacity (FBC), OAB symptom scores (OABSS), and incontinence quality of life questionnaire (I-QoL) scores were collected before and after treatment. The therapeutic efficacy was evaluated using the Nimodipine method. Results After 12 weeks of treatment, the 24-hour urination indicators in both groups including daytime urination frequency, nocturia frequency, urgency episodes and FBC, as well as OABSS and I-QoL scores, showed a significant improvement compared to baseline (P<0.001). The combined treatment group exhibited fewer urgency episodes than the TTNS group [ (1.07±0.66) times/24 h vs. (1.64±0.62) times/24 h, P<0.05]. However, no statistically significant differences were observed between the two groups in other urinary parameters (P>0.05). The total effective rate in the combined treatment group was 96.43%, which was significantly higher than that in the TTNS group (82.14%, P<0.05). During treatment, one patient (3.57%) in the TTNS group experienced mild skin allergy, which recovered following symptomatic management. Conclusion The combination of TTNS and Mirabegron in drug-refractory OAB not only alleviates clinical symptoms and improves quality of life, but also shows superior efficacy in reducing urgency episodes. This approach is a safe and effective treatment option.
